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ABSTRACT
Although endocrine therapy is successfully used to treat patients with estrogen 
receptor (ER) positive breast cancer, a substantial proportion of this population will 
relapse. Several mechanisms of acquired resistance have been described including 
activation of the mTOR pathway, increased activity of CDK4 and activating mutations in 
ER. Using a patient derived xenograft model harboring a common activating ER ligand 
binding domain mutation (D538G), we evaluated several combinatorial strategies 
using the selective estrogen receptor degrader (SERD) fulvestrant in combination 
with chromatin modifying agents, and CDK4/6 and mTOR inhibitors. In this model, 
fulvestrant binds WT and MT ER, reduces ER protein levels, and downregulated ER 
target gene expression. Addition of JQ1 or vorinostat to fulvestrant resulted in tumor 
regression (41% and 22% regression, respectively) though no efficacy was seen 
when either agent was given alone. Interestingly, although the CDK4/6 inhibitor 
palbociclib and mTOR inhibitor everolimus were efficacious as monotherapies, long-
term delayed tumor growth was only observed when co-administered with fulvestrant. 
This observation was consistent with a greater inhibition of compensatory signaling 
when palbociclib and everolimus were co-dosed with fulvestrant. The addition of 
fulvestrant to JQ1, vorinostat, everolimus and palbociclib also significantly reduced 
lung metastatic burden as compared to monotherapy. The combination potential of 
fulvestrant with palbociclib or everolimus were confirmed in an MCF7 CRISPR model 
harboring the Y537S ER activating mutation. Taken together, these data suggest that 
fulvestrant may have an important role in the treatment of ER positive breast cancer 
with acquired ER mutations.
INTRODUCTION
Breast cancer patients are subtyped based on the 
estrogen receptor (ER), progesterone receptor (PR), and/
or ERBB2 (HER2) status of the tumor. The majority of 
patients presenting with ER+ disease can be successfully 
treated with endocrine therapies that block the production 
and/or activity of estrogen, thus depriving the tumor of 
its main driver for growth. Recommended hormonal 
depletion approaches depend on a women’s menopausal 
status and may include treatment with aromatase inhibitors 
(AI), selective estrogen receptor modulators (SERM) and 
selective estrogen receptor degraders (SERD). Despite 
a multitude of clinical strategies to overcome estrogen 
signaling to the tumor, patients often become refractory 
and acquire endocrine resistant disease [1]. Recently, 
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combination strategies of AIs with targeted agents for 
CDK4/6 (palbociclib) or mTOR (everolimus) have been 
approved for patients with metastatic disease. While 
the results from the combination approaches have been 
encouraging, the responses do not appear to extend overall 
survival. Although SERDs such as fulvestrant provide an 
additional endocrine strategy for reducing ER signaling, 
acquired resistance can emerge as well [2] and further 
reinforces the need to better understand mechanisms of 
resistance and evaluate combinatorial strategies.
Several mechanisms of endocrine resistance 
have been described including the overexpression or 
amplification of HER2 [1-3] as well as mutations causing 
hyperactivation of the PI3K pathway [4, 5]. Recently, 
evidence of activating mutations in ER were described in 
tumors from patients with metastatic disease progressing 
on endocrine therapies [6-12]. To test the function of 
ER ligand binding domain (LBD) mutations in vitro, 
studies overexpressing a panel of ER LBD variants 
have demonstrated that ER mutations can promote 
ligand-independent activity and cellular growth [6-11]. 
Interestingly, Yu, et al generated cell lines from patient 
derived circulating tumor cells harboring recurrent 
mutations in ER and PIK3CA and performed an ex vivo 
compound screen [11]. The data demonstrated that 
SERDs can inhibit in vitro growth of these cell lines with 
the potential for more robust responses when used in 
combination with other targeted agents dependent on the 
genetic profile of the tumor. Unfortunately, cell lines with 
endogenous activating ER mutations are rare, limiting the 
ability to test in vivo. Patient derived xenograft (PDX) 
breast cancer models harboring ER mutations have 
recently been reported, and are useful tools for preclinical 
discovery. Li, et al described a PDX model harboring 
a Y537S ER mutation that recapitulated the estrogen 
independence observed in the patient from which the 
model was derived [6]. 
One strategy to block ligand-independent ER 
signaling is by inhibiting ER’s function as a transcription 
factor by altering the chromatin state. To this end, it was 
recently demonstrated that JQ1, an inhibitor of the BET 
family of transcriptional regulators, suppressed ER activity 
and growth in tamoxifen-resistant cells [13]. Additionally, 
HDAC inhibition with vorinostat resensitized tamoxifen-
resistant cells and resulted in synergistic growth inhibition 
with SERMs/SERDs [14]. In addition to ER mutation, 
activation of the mTOR pathway has been shown to 
promote acquired resistance to endocrine therapy [4], 
leading to the use of mTOR inhibitors such as everolimus 
in advanced breast cancer [15-17]. Indeed, while the 
BOLERO-2 trial reported promising results including 
increased progression-free survival when combining 
everolimus with an aromatase inhibitor [16, 17], there 
was no significant increase in overall survival [18]. 
Additionally, CDK4 has also been shown as a driver of 
estrogen independence [19] and the CDK4/6 inhibitor 
palbociclib selectively inhibits the growth of luminal 
ER+ cell lines [20, 21]. Given these observations, the 
PALOMA-1 trial evaluated the efficacy of palbociclib 
with an aromatase inhibitor and demonstrated an increase 
in progression free survival [22]. Collectively, these data 
warrant testing of SERDs with chromatin modifying 
agents and inhibitors of mTOR and CDK4 pathways in 
ER mutant breast cancer models. 
In this report, we describe a CTX model (circulating 
tumor cell xenograft) with commonly co-occurring 
mutations including a recurrent ER mutation (D538G) 
[7, 9] that recapitulates clinically observed endocrine 
resistance. We demonstrate that this mutant ER protein is 
susceptible to degradation with fulvestrant. Despite this, 
the model remains only partially responsive to fulvestrant 
and insensitive to tamoxifen, potentially due to its 
complex genetic profile. The combination of fulvestrant 
with palbociclib or everolimus resulted in sustained tumor 
growth inhibition after treatment withdrawal and blocked 
the compensatory feedback observed with palbociclib or 
everolimus alone. Furthermore, while JQ1 or vorinostat 
alone altered binding of ER to chromatin and decreased 
target gene expression in the D538G background, 
these compounds only resulted in regressions when 
combined with fulvestrant. We also observed that all of 
the fulvestrant combinations decreased metastatic tumor 
burden. Finally, we tested fulvestrant in combination with 
palbociclib or everolimus in MCF7 cells with a different 
activating ER mutation (Y537S) engineered into the 
ligand binding domain using CRISPR. In this cell line, 
we again observed estrogen independent growth, partial 
sensitivity to fulvestrant, and an additive effect when 
combining fulvestrant with palbociclib or everolimus. 
Here, we describe clinically relevant models of ER mutant, 
endocrine resistant breast cancer and provide evidence 
that combination therapies including SERDs may benefit 
patients with activating ER mutations. 
RESULTS
Characterization of endocrine resistant breast 
cancer by a CTX harboring an ER D538G 
mutation
We molecularly characterized a panel of 15 PDX 
models to elucidate the genomic mutations underpinning 
disease, five of which were ER+. Of the five models 
characterized, we identified one model, CTC-174, 
which harbors an ER D538G mutation, found at 31% 
allele frequency (Table S1). This model was generated 
from circulating tumor cells implanted orthotopically 
into immunocompromised mice (referred to as a CTX 
model). The circulating tumor cells were obtained from a 
63-year-old patient with stage IV ER+ breast cancer after 
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42 days of fulvestrant therapy and 26 days of eribulin 
therapy. Although the patient had significant clinical 
improvement when the cells were collected, the patient 
presented with progressive metastatic disease 63 days 
later. Gene signature analyses suggested the model was 
representative of a luminal B subtype (Table S1, data not 
shown). Immunohistochemistry (IHC) of the implanted 
tumor confirmed this model was ER+/PR+/Her2 low, 
which was observed in the presence and absence of 
exogenous estrogen (Figure 1A). In addition, this model 
harbored other co-occurring oncogenic drivers including 
an activating PIK3CA mutation [7](Table S1). 
To determine the metastatic potential of CTC-174 in 
mice, we analyzed lung, liver, and kidney for the presence 
of human cancer cells. By immunohistochemistry (IHC) 
analysis, human cells were detected in lung tissue, 
suggesting this model possessed the ability to metastasize 
in an animal model (Figure 1B, data not shown). We 
validated the IHC results with PCR and observed 
significantly more human GAPDH RNA in the lungs 
compared to other tissues, consistent with IHC results 
(Figure 1C). We did not detect metastases in the kidney 
or liver (data not shown). The metastatic potential of 
this model allows for evaluation of a clinically valuable 
secondary endpoint. 
Next, we wanted to determine if this model was 
estrogen independent, similar to previously reported ER 
mutant (D538G) models. Although most ER+ PDX models 
are estrogen dependent and require exogenous estrogen 
for growth, CTC-174 displayed similar growth kinetics 
in the presence or absence of estrogen supplementation 
(Figure 1D) and exhibited constitutive ER activity 
without estrogen supplementation (Figure S1). Using 
this model without exogenous estrogen more accurately 
recapitulated the tumor environment from which the 
model was derived (a postmenopausal woman); and all 
subsequent in vivo studies were therefore performed in 
the absence of exogenous estrogen. We next wanted to 
evaluate sensitivity of the model to tamoxifen, a SERM 
that is the current standard of care for ER+ breast cancer. 
In mice bearing CTC-174 tumors, only modest tumor 
growth inhibition with tamoxifen treatment was observed 
(Figure 1E, S2A). As expected, we observed a partial 
tumor growth inhibition (TGI = 59%) with fulvestrant 
(Figure 1E, S2A) in CTC-174, consistent with the clinical 
outcome of the patient. 
To determine if the partial activity of fulvestrant 
was due to an altered ability to degrade mutant ER, we 
measured changes in ER protein levels and observed 
significant degradation (Figure 2A). Consistent with 
this, we observed downregulation of ER target gene 
expression (Figure 2B) suggesting fulvestrant is targeting 
the ER mutant protein as well as the WT ER allele. 
We hypothesized that the residual ER protein/activity 
observed was due to a reduced ability of fulvestrant to 
target the D538G ER protein and that treatment with 
fulvestrant would enrich for cells with high expression of 
the D538G ER allele. To test this, we used a PCR-based 
genotyping assay to measure the expression of the D538G 
vs. WT ER. Importantly, we did not observe a selection 
for cells with elevated expression of the D538G ER allele 
or increase in the abundance of the genomic D538G ER 
(Figure 2D). To further determine whether fulvestrant can 
target the D538G ER protein, we directly measured the 
ability of fulvestrant to displace 1.5nM estrogen from a 
GST-tagged ER ligand binding domain (LBD) of either 
the WT or D538G ER (amino acids 307-554) using time-
resolved fluorescence resonance energy transfer (TR-
FRET) (Figure 2E-2F). The results demonstrated that 
fulvestrant binds both the D538G-LBD and WT-LBD 
with low nanomolar affinity, and the EC50 of D538G-LBD 
was 2.26 fold higher than the EC50 of the WT-LBD (Figure 
2F). Additionally, the EC50 towards both peptides was 
below the steady state plasma concentration of fulvestrant 
in patients, [23-25] suggesting fulvestrant should bind 
the D538G protein as well as WT and target them for 
degradation in vivo. To further test our hypothesis that 
fulvestrant would target mutant forms of ER, we generated 
MCF7 stable cell lines with a doxycycline inducible 
FLAG-WT or FLAG-D538G ER. After 72hrs of 20nM 
fulvestrant treatment, endogenous ER, FLAG-WT and 
FLAG-D538G ER proteins were degraded 80.6%, 79.0% 
and 73.5%, respectively and were not statistically different 
(Figure 2G-2H). Collectively, these data demonstrate that 
fulvestrant targets both the WT and D538G ER proteins 
for degradation and inhibits ER signaling, suggesting 
that the partial response observed in vivo is not due to an 
inability of fulvestrant to target the ER mutant protein. 
Efficacy of fulvestrant with JQ1, vorinostat, 
palbociclib or everolimus in the D538G ER CTX 
model
Patients that have acquired endocrine resistance 
will progress to combination therapies that often include 
an endocrine agent. Because we have determined that 
fulvestrant is capable of targeting the D538G ER protein, 
including SERDs such as fulvestrant in these combination 
therapies may provide additional anti-tumor activity. We 
assessed the combination efficacy of fulvestrant with the 
chromatin modifying agents, JQ1 (BET family inhibitor), 
vorinostat (class I and II HDAC inhibitor), palbociclib 
(CDK4/6 inhibitor) and everolimus (TORC1 inhibitor). 
Importantly, all of these agents were well tolerated in 
combination with fulvestrant (data not shown). Treatment 
with JQ1 alone resulted in a 78% TGI, while vorinostat 
alone had little to no efficacy. Surprisingly, both JQ1 and 
vorinostat resulted in tumor regressions when combined 
with fulvestrant (Figure 3A-3B). Significant efficacy was 
observed with palbociclib or everolimus monotherapy 
(Figure 3C-3D). Although fulvestrant combination with 
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Figure 1: Human CTX model harboring D538G mutation recapitulates endocrine resistant, ER+ disease and 
metastasizes to the lungs. A. Representative immunohistochemical staining of ER/PR/Her2 of tumors from CTC-174 tumor bearing 
mouse supplemented with estrogen pellets (0.18mg/90d) (top) and without estrogen supplementation (bottom). B. Human specific DNA-
PKcs staining of a representative metastatic CTC-174 lung lesion. C. Detection of tumor tissue in tumor and mouse tissues using PCR 
for human and mouse GAPDH. Data represents the fold change of human GAPDH compared with mouse GAPDH. N = 3, * indicates p 
< 0.05. D. Tumor growth in vehicle treated animals +/- estrogen supplementation (0.18mg/90d). N = 7 animals. E. Efficacy of tamoxifen 
and fulvestrant in CTC-174 tumors. N≥7 animals. Bars represent SEM. Tamoxifen tumor growth inhibition (TGI) = 40.21%, p = 0.0546, 
Fulvestrant TGI = 66.54%, p = 0.0001. 
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Figure 2: Fulvestrant can degrade the D538G mutant ER protein. A. Western blot measuring ER protein levels from vehicle 
or fulvestrant treated animals at the end of the study (Figure 1D, n = 3 animals/treatment, Fulvestrant decreased ER 72.5%, p = 0.0004). 
GAPDH used as a loading control. B. PCR measuring ER target gene expression from vehicle or fulvestrant treated animals. C. Genotyping 
of ER cDNA. Data represented as the relative fold change of D538G ER over WT ER alleles relative to vehicle control. D. Genomic WT vs. 
D538G ER DNA represented as in C.. E. Fulvestrant binding to the ligand binding domain of WT or D538G ER measured by displacement 
of 1.5nM estrogen. Vertical line indicates the plasma C-min observed in the CONFIRM trial [25]. F. EC50 calculated from E. as described in 
the methods/materials. p = 9.79217E-14. G. Western blot analyses of the indicated proteins in MCF7 cells stably expressing a doxycycline 
inducible FLAG-WT or D538G ER treated with 20nM fulvestrant for 72 in the presence of 1ug/ml doxycycline. Vinculin was used as a 
loading control. H. Quantification of western blot from G. normalized to the respective untreated control. Histogram represents the average 
of 3 replicates. Bars represent SEM. N.S. = not significant (p = 0.2443) 
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palbociclib or everolimus were statistically different 
from the respective single agent group (p = 0.0003 and p 
= 0.0075, respectively), the efficacy observed with each 
agent alone made it difficult to conclude if the combination 
with fulvestrant was beneficial (Figure 3C-3D). 
In addition to measuring efficacy by orthotopic 
tumor growth, we monitored tumor burden in the lung as 
a secondary endpoint. Animals treated with palbociclib or 
everolimus had significantly reduced lung tumor burden 
while the chromatin modifying agents JQ1 or vorinostat 
showed little effect compared to vehicle treatment (Figure 
3E). Each combination group had significantly less lung 
tumor burden than vehicle treated animals (Figure 3E). 
Strikingly, fulvestrant in combination with JQ1 resulted 
in the most pronounced reduction of lung metastases 
despite the combination having a similar effect on primary 
tumors as other combinations. Metastatic lesions were 
also quantified by IHC staining of human DNA-PKcs 
in three random regions of the lung. The results further 
demonstrated that fulvestrant combinations decreased 
metastases compared to each respective agent alone 
(Figure S2B) suggesting that degrading ER in combination 
with other agents provides benefit for both primary and 
secondary endpoints. 
To test if any agent provided a growth advantage 
for cells with increased D538G ER levels (relative to WT 
ER), we measured changes in the expression of the D538G 
and WT ER alleles following combination treatments 
(similar to Figure 2C-2D). None of the treatments resulted 
in a significant change in the ratio of the D538G and WT 
ER alleles, consistent with previous experiments (Figure 
3F, S2C). In addition, none of the agents used in the 
combination groups altered the ability of fulvestrant to 
degrade ER (Figure 3G). 
Chromatin modifying agents alter ER function in 
the presence of an ER mutation
Previous studies have demonstrated that altering 
chromatin state may provide a mechanism of inhibiting 
ER. For example, the BET family inhibitor, JQ1, can 
decrease the expression of ER target genes such as 
TFF1 in tamoxifen resistant cells [13]. Furthermore, 
it has been shown that HDACs associate with ER [26, 
27], and are directly involved in the regulation of TFF1 
[28], and that HDAC inhibition can resensitize resistant 
cells to tamoxifen [29]. In the D538G ER mutant model, 
the chromatin modifying agents vorinostat and JQ1 
decreased the expression of TFF1, and was augmented 
by combination with fulvestrant (Figure 4A). In addition 
to altering TFF1 expression, both vorinostat and JQ1 
decreased the expression of PR as well (Figure 4B). 
Finally, the decrease in ER target genes was specific to the 
chromatin modifying agents as palbociclib and everolimus 
did not result in decreases in ER target genes (TFF1, PR 
and GREB1) (Figure S3A). 
Because vorinostat or JQ1 alone do not decrease 
ER protein levels, this suggests the altered ER target gene 
expression was a direct result of inhibiting ER function. 
To address this possibility, we performed chromatin 
immunoprecipitation (ChIP) of ER at the promoters 
and/or enhancer regions of ER target genes from tumor 
samples. Consistent with previous reports, fulvestrant 
treatment alone resulted in decreased ER binding to target 
genes [30] (Figure 4C). While vorinostat treatment slightly 
increased ER protein expression (Figure 3G), overall 
binding of ER to target genes was decreased (Figure 
4C). As expected, the combination of vorinostat and 
fulvestrant resulted in a decrease in ER binding relative 
to the vehicle control (Figure 4C, S3B). Interestingly, the 
combination of vorinostat and fulvestrant trended towards 
increased ER occupancy at ER target gene promoters and 
enhancers compared to each single agent alone, while 
the expression of the target genes trended in the opposite 
direction. We also observed a decrease in ER occupancy 
after JQ1 treatment (Figure 4C), which is consistent with 
reports that JQ1 decreases the chromatin marks associated 
with active transcription in MCF7 cells at ER target 
genes [13]. We were unable to assess the occupancy of 
ER at target genes after JQ1 and fulvestrant treatment 
due to the consistent tumor regressions observed with 
this combination. Collectively, these data suggest that 
chromatin modifiers such as vorinostat or JQ1 enhance 
the efficacy of fulvestrant by indirectly modulating ER 
transcriptional activity. 
Compensatory feedback loops after palbociclib 
or everolimus treatment are mitigated by 
combination therapies
Previous studies demonstrated that treatment with 
palbociclib increased the protein levels of cyclinD1 
[31, 32], which can promote ER activity independent of 
CDK4 [33-35]. Although the combination of palbociclib 
and fulvestrant was statistically better than palbociclib 
alone (Figure 3C), palbociclib was efficacious as a single 
agent. Therefore, we evaluated whether combining 
fulvestrant with palbociclib could provide a benefit by 
blocking the feedback signaling observed with palbociclib 
treatment [31]. First, we confirmed that palbociclib alone 
or in combination with fulvestrant decreased p780 Rb, 
an established biomarker of palbociclib activity [21] 
(Figure 5A). Consistent with these findings, we observed 
a significant increase in cyclinD1 protein levels with 
palbociclib (Figure 5A, S4A). Importantly, fulvestrant 
decreased cyclinD1 expression and blocked the increase 
observed with palbociclib when used in combination 
(Figure 5A). We also observed a similar trend with 
cyclinD1 mRNA levels (Figure 5B). Furthermore, 
palbociclib resulted in a greater than additive decrease 
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Figure 3: Efficacy of current therapeutic options with fulvestrant in a D538G ER background. A.-D. Combination 
therapies with palbociclib (Palbo), vorinostat (Vor), JQ1 or everolimus (Eve) and fulvestrant (Ful) were performed in ovariectomized mice 
as indicated. 3A-B, 3D were performed in the same experiment and data was separated into individual graphs for clarity. N = 8. Palbociclib 
was tested separately and is represented with the matched vehicle and fulvestrant group. N = 10. Bars represent the SEM. Relative to 
vehicle-treated tumors: JQ1 TGI = 78%, p < 0.0001. JQ1+Ful = 41% regression, p < 0.0001. Vor TGI = 21%, p = 0.1189. Vor+Ful = 22% 
regression, p < 0.0001, Palbo TGI = 98%, p < 0.0001, Palbo+Ful = 30% regression, p < 0.0001. Eve = 33% regression, p < 0.0001. Eve+Ful 
= 62% regression, p < 0.0001. Ful for 3A-B, D TGI = 92%, p < 0.0001, 3C TGI = 83%, p < 0.0001. Relative to fulvestrant alone, Vor+Ful 
p = 0.0019. Eve vs. Eve+Ful p = 0.0075, Palbo vs. Palbo+Ful p = 0.0003 E. Detection of lung metastasis at the end of dosing from Figure 
, 3A-3D (N = 3). Samples were collected 24hr post fulvestrant and 4hr post-treatment for other agents. * p < 0.05 compared to vehicle. 
Tam = Tamoxifen F. Genotyping of WT ER vs. D538G ER in cDNA as in Figure 2E. No statistical significance was observed relative to 
the vehicle. G. Western blot measuring ER from 3 representative animals represented in 3A-D. Vinculin was used as a loading control. 
Oncotarget8www.impactjournals.com/oncotarget
in CDC25A, a marker associated with cell cycle 
progression, when combined with fulvestrant (Figure 
5B, right). Collectively, these results demonstrate that 
the combination of palbociclib with a SERD may benefit 
patients by blocking the compensatory signaling observed 
with palbociclib alone and further decrease the expression 
of genes required for cell cycle progression. 
Similar to palbociclib, everolimus exhibited 
monotherapy response in the CTC-174 model. (Figure 3D). 
To determine whether there was a combination benefit with 
everolimus and fulvestrant, we evaluated several markers 
of mTOR and AKT activity post-treatment. As expected, 
everolimus treatment decreased pS6-S240/244 and 
p4EBP1-S65 (Figure 5C, S4B). Fulvestrant also decreased 
pS6-S240/244 and p4EBP1-S65, albeit to a lesser extent 
than everolimus (Figure 5C). Interestingly, tamoxifen 
increased total and phosphorylated S6 and 4EBP1 as well 
as total AKT (Figure 5C, S4B), highlighting the benefit ER 
degradation with fulvestrant compared to ER modulation 
with tamoxifen. Previous studies have demonstrated 
that inhibition of TORC1 with everolimus results in 
a compensatory increase in TORC2 mediated AKT 
activation and the abrogation of AKT signaling enhances 
the effects of everolimus inhibition [36-38]. We observed 
similar compensatory AKT activities in our model (Figure 
5C). Interestingly, fulvestrant decreased pAKT-S473 and 
pAKT-T308 and blocked the everolimus-induced increase 
in pAKT (Figure 5C), suggesting a mechanistic benefit 
for combining fulvestrant with everolimus. Together, 
these results demonstrate ER degradation can enhance 
mTOR inhibition with everolimus in a D538G ER, mutant 
PIK3CA background. 
Figure 4: ER target gene expression and promoter/enhancer binding are decreased by the chromatin modifier 
inhibitors vorinostat and JQ1. A.-B. PCR of TFF1 and PR from indicated animals in 3A, B. Each point represents the average of 3 
animals, bars represent SEM. C. Chromatin immunoprecipitations (ChIP) was performed against ER in tumors represented in Figure 3. 
The ‘negative region’ is a negative control describing a genomic position downstream of the PR binding site. *p < 0.05, **p < 0.005 and is 
compared to vehicle unless otherwise indicated. Rabbit IgG are shown in Figure S2. 
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Figure 5: Feedback signaling from CDK4/6 (palbociclib) or mTOR (everolimus) inhibition is blocked by ER degradation 
in the D538G ER background. A. Western blot of p780 RB and cyclinD1. B. Gene expression of cyclinD1 (left) and CDC25A (right) 
from Figure 3C. Each point represents the average of 3 animals. Bars represent SEM. *p < 0.05, **p < 0.005 C. Western blot analyses of 
tumors from animals represented in Figure 3D. Vinculin was used as a loading control. Quantification displayed in Figure S3.
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Concurrent inhibition of ER and CDK4/6 or 
mTOR leads to delayed tumor growth
Our data demonstrates that ER degradation can 
inhibit feedback signaling observed with palbociclib 
and everolimus and suggests that adding fulvestrant 
with either of these compounds may present a clinically 
beneficial strategy. To test this hypothesis further, we 
continued measuring tumor growth in groups where tumor 
regressions were observed. After discontinuing treatment 
with palbociclib or everolimus alone, tumors resumed 
growth at a similar rate as the vehicle treated animals 
(Figure 6A-6B, S5A-S5B), and was further confirmed by 
the quantification of tumor doubling time (Figure 6C-6D). 
Importantly, tumors from animals treated with fulvestrant 
alone or the fulvestrant/palbociclib combination had 
significantly delayed doubling time (5.71 and 4.77 fold 
slower relative to vehicle, respectively) (Figure 6C). 
Similarly, animals treated with fulvestrant and everolimus 
had significantly delayed tumor growth relative to 
vehicle (2.18 fold slower relative to vehicle) (Figure 6D). 
Collectively, fulvestrant alone or in combination with 
palbociclib or everolimus clearly delayed tumor regrowth 
and provides mechanistic rationale for evaluation in the 
clinic. 
Efficacy of fulvestrant with palbociclib or 
everolimus in an engineered MCF7 ER Y537S 
xenografts
Our data in the ER mutant CTC-174 model suggests 
a benefit for combining fulvestrant with either palbociclib 
or everolimus. To confirm these observations in an 
additional model, we introduced several clinically relevant 
ER mutations into MCF7 cells using CRISPR/Cas9. These 
efforts yielded a polyclonal MCF7 cell line with a Y537S 
mutation in one ER allele and a frameshift mutation in 
another ER allele (ER-Y537S/KO). Consistent with 
Figure 6: More durable responses with are achieved when palbociclib and everolimus are combined with fulvestrant. 
A.-B. At least 5 animals from Figure 3C were allowed to regrow tumors after dosing with palbociclib alone or in combination with 
fulvestrant. A. Mean tumor volume. Arrow represents 21 dosing day period. B. Individual animal tumor growth starting from the end of 
dosing. C.-D. Tumor doubling times after ending treatment from animals treated with fulvestrant and/or palbociclib C. or everolimus D.. 
Bars represent SEM. ** p < 0.005, *** p < 0.0005.
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the loss of an ER allele, the MCF7-Y537S/KO cell line 
has lower ER expression relative to the parental MCF7 
cell line (Figure S6A). Additionally, when implanted in 
mice supplemented with estrogen pellets, we observed 
continuous tumor growth of MCF7-Y537S/KO cells in 
vivo after removing the estrogen pellets (Figure S6B), 
which is similar to previous overexpression studies [7]. 
We then assessed the efficacy of palbociclib or everolimus 
in combination with fulvestrant. Unlike CTC-174, no 
single agent treatments exhibited in tumor regressions 
(TGI of 52%, 50% and 62% for fulvestrant, everolimus 
and palbociclib, respectively) (Figure 7A-7B). The 
combination of palbociclib and fulvestrant resulted in a 
greater tumor growth inhibition (5% regression) than 
either agent alone, similar to previous reports in a PDX 
model with an ER-Y537S mutation [39]. The combination 
of everolimus and fulvestrant resulted in a 76% TGI 
suggesting the combination of fulvestrant and everolimus 
is additive in this model (Figure 7B). Together, these data 
provide a second ER mutant model demonstrating that 
the addition of fulvestrant to palbociclib and everolimus 
treatments will provide benefit in ER mutant breast 
cancers. 
DISCUSSION
ER+ breast cancers bearing activating ER mutations 
represent a new segment of endocrine resistant disease 
with an unmet therapeutic need. To investigate potential 
strategies to target these tumors, we developed an ER+ 
breast cancer CTX model from circulating tumor cells 
of a patient that harbors a D538G ER mutation, CTC-
174. This mutation promotes estrogen independent ER 
activity and have been reported in patients who have 
acquired endocrine resistance [7, 9, 10, 40]. Indeed, 
our model recapitulates endocrine therapy resistant 
disease as shown by estrogen independent growth and 
resistance to tamoxifen. Using this model, as well as in 
vitro approaches, we demonstrated that fulvestrant targets 
the mutant ER protein for degradation but only provides 
modest growth inhibition in vivo, suggesting additional 
pathways may promote resistance to endocrine therapy.
Clinically, combinatorial strategies for AI refractory 
ER+ breast cancer have yielded encouraging results. 
The BOLERO-2 and PALOMA-1 trials both achieved 
increased progression free survival by combining an 
aromatase inhibitor with everolimus or palbociclib, 
respectively [16, 22]. Given that activating ER mutations 
are acquired most frequently in patients who have 
previously received an aromatase inhibitor [40], the 
combination of everolimus or palbociclib with a SERD 
such as fulvestrant may provide superior efficacy in these 
patients by lowering ER expression and could potentially 
increase overall survival [18]. Recently, the PALOMA-3 
trial evaluating palbociclib combined with fulvestrant 
demonstrated longer progression free survival compared 
to fulvestrant alone [41]. Future follow-up with these 
patients may ultimately determine if this combination 
increases overall survival in patients with ER mutations. 
In support of this hypothesis, we demonstrate that our ER 
Figure 7: Efficacy of palbociclib or everolimus with fulvestrant in a MCF7-Y537S/KO background. A.-B. Combination 
therapies of fulvestrant (Ful) with either palbociclib (Palbo) or everolimus (Eve) were performed in nude mice. All treatments were dosed 
in the same experiment and separated for clarity. N = 11. Bars represent SEM. Relative to vehicle: fulvestrant TGI = 52%, p = 0.0118, 
palbociclib TGI = 62%, p = 0.0032, Palbo+Ful = 5% regression, p < 0.0001, everolimus TGI = 50%, p = 0.0177, Eve+Ful TGI = 76%, p 
= 0.0002. 
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mutant models are estrogen independent and therefore 
unlikely to respond to an aromatase inhibitor and that 
fulvestrant is effective at degrading WT and MT forms 
of ER. Furthermore, we demonstrate that although 
everolimus and palbociclib are efficacious in the CTC-
174 model (D538G ER, N345K PIK3CA), more potent 
tumor regressions were observed when these agents were 
combined with fulvestrant. In a second MCF7 model 
(Y537S ER, E545K PIK3CA), we observed increased 
tumor growth inhibition when fulvestrant was combined 
with palbociclib or everolimus. These observations suggest 
combinations with fulvestrant will benefit patients with 
estrogen independent breast cancers harboring a D538G 
or Y537S ER mutations and similar genetic drivers. These 
ER mutations are only two of several recently reported 
mutations [6-10], and therefore it will be important to test 
the ability of fulvestrant to target other ER mutations. 
We also hypothesized that despite degradation of the 
mutant ER protein, the residual ER protein is sufficient 
to promote tumor growth and additional strategies will 
be necessary to achieve clinical benefit. Inhibiting ER 
transcriptional activity by changing chromatin state with 
chromatin modifying agents might therefore provide 
additional benefit. In support of this, we observed 
downregulation of the several ER target genes, upon 
treatment with chromatin modifying agents JQ1 and 
vorinostat. In some instances, (such as TFF1), combining 
chromatin modifying agents with fulvestrant resulted 
in stronger downregulation than either single agent, 
although this coincided with an unexplained trend towards 
increased ER occupancy at ER target gene promoters and 
enhancers compared to each single agent. Interestingly, 
vorinostat treatment resulted in decreased gene expression 
of both TFF1 and PR, despite having minimal impact on 
tumor growth. Vorinostat has a short half-life [42, 43], 
therefore, may not produce sufficient exposure to result in 
tumor growth inhibition due to only transient inhibition of 
ER function. Additionally, combining fulvestrant with JQ1 
resulted in substantial decreases in the metastatic tumor 
burden, which could be the result of increased ability to 
inhibit growth of tumor cells in the lung or extravasate 
from the orthotopically-implanted tumor. Future work will 
be required to test these possibilities. Collectively, these 
data suggest that developing new epigenetic agents that 
can inhibit ER activity is warranted. 
In addition to causing tumor regression, all of 
our combination therapies decreased metastatic tumor 
burden. Metastases are the primary cause of death from 
solid tumors and present a common therapeutic challenge 
in patients [44]. Therefore, our CTX model provides a 
valuable tool for testing the impact of novel compounds 
on metastasis in future drug development.
In conclusion, many of the clinical trials currently 
enrolling endocrine resistant breast cancer patients will 
include an endocrine therapy in combination with new 
targeted therapies. Our data suggests including a SERD 
will provide superior efficacy to an aromatase inhibitor in 
the patients enrolled in these trials. Several oral SERDS 
have been developed and have yielded promising results 
[45-48]. Our results demonstrate that mutant ER can 
be targeted with fulvestrant and suggests that SERDs 
with activity against mutant ER should be prioritized. 
Collectively, our study indicates that degrading ER in 
an endocrine resistant, estrogen independent, ER mutant 
model can provide a therapeutic benefit and suggests that 
fulvestrant may have an important role in the treatment 
of ER positive breast cancer with acquired ER mutations. 
MATERIALS AND METHODS
Generation of the CTX model/efficacy studies
Blood samples from MBC patients, consented 
according to the Human Biological Samples Policy, were 
purchased from Conversant Biologics. Due to patient 
confidentiality, minimal patient history was provided 
and previous endocrine therapy treatments are unknown. 
PBMCs were prepared using Lympholyte®-H (Cedar Lane 
Labs), EpCAM+CD44+ cells were isolated (manuscript in 
preparation), and placed into 6-well ultra-low attachment 
plates (Corning) with the Mammocult medium (Stem 
Cell Technologies). After 9 days in culture, cells were 
suspended in phosphate buffered saline (PBS), counted 
with a hemocytometer, and resuspended in PBS mixed 
with high concentration matrigel (BD Biosciences) at 10 
mg/mL. Each aliquot of 0.2 mL containing 650 cells was 
orthotopically injected into the third mammary fat pad of 
three NOD/SCID (Cg-Prkdcscid Il2rgtm1Wjl/SzJ) (NSG) 
mice pre-implanted with estrogen pellets (0.36mg/90day). 
For efficacy studies with CTC-174, tumor fragments were 
implanted in the mammary fat pads of NSG mice (Jackson 
Labs) by standard techniques. For MCF7-Y537S/KO 
cells, nude mice (Taconic) were injected with 1x107 cells 
subcutaneously in 1:1 PBS/Matrigel (Corning). Efficacy 
studies in MCF7-Y537S/KO cells were performed 
without estrogen supplementation. To measure estrogen 
independent growth, mice were pre-implanted with 
0.72mg/90 day estrogen pellets (Innovative Research of 
America) subcutaneously using a 10g trocar 48 hours prior 
to cell implantation, as instructed by the manufacturer. 
Estrogen pellets were removed using standard surgical 
techniques when the MCF7-Y537S/KO group average 
was approximately 500mm3. When estrogen pellets were 
used in CTC-174, 0.18mg/90 day (Innovative research 
of America) were implanted at the time of orthotopic 
tumor implant. Animals were ovariectomized (by Jackson 
Labs) for combination efficacy studies (Figure 3). 
Doses of JQ1 [49, 50], vorinostat [51], palbociclib [19, 
21] and everolimus [52, 53] were matched to clinically 
relevant exposures as previously described. Fulvestrant 
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was administered weekly in a 100μl injection of clinical 
grade/formulation of fulvestrant at 50mg/ml. All analysis 
of tumor/lung samples at the end of dosing in figures 3-5 
were performed using 3 representative animals. All tumor 
doubling times reflect growth from the last day of dosing 
until the last measurement. A doubling time for every 
animal in the respective group was generated using a best-
fit exponential curve using by non-linear regression then 
averaged (prism 6). Each point represents the average 
of at least 5 animals, bars represent SEM. Stars indicate 
a p-value < 0.05. All procedures were performed in 
accordance with federal, state and Institutional guidelines 
in an AAALAC-accredited facility and were approved by 
the MedImmune or AstraZeneca Institutional Animal Care 
and Use Committee (IACUC).
RNA sequencing/CGH array
Transcriptome resequencing was performed on an 
Illumina HiSeq 2000. Raw sequences were first quality 
assessed and low quality reads were removed. The clean 
reads were then aligned to both human (hg19) and mouse 
(mm10) using TopHat. In-house customized analysis 
pipeline was used to separate human and mouse sequences 
using alignment qualities [54]. Mouse sequences were 
then filtered from human alignment before downstream 
analysis. Expression was quantified into RPKM using 
and RSeQC. Variants from RNA-seq were called by an 
in-house variant caller VarDict. Mutations were identified 
after filtering common SNPs and non-functional variants, 
such as silent and those in UTR or introns.
Immunohistochemistry and chromatin 
immunoprecipitation
Tumors and lungs Immunohistochemistry was 
performed using the Ventana Discovery XT according 
to manufacturer’s instructions. All ChIP experiments 
were performed as previously described [55] with the 
following modifications: tumors were snap frozen in liquid 
nitrogen, crushed to powder and resuspended in 8ml 1% 
formaldehyde at room temperature. 
Time-resolved fluorescence resonance energy 
transfer
GST-tev-WT or D538G (residues 307-554) were 
expressed in E. coli, purified by GST capture followed 
by size exclusion then ion exchange chromatography. 
Binding was measured with a LanthaScreen kit (Life 
Technologies). 
Gene expression and genotyping of ER
All gene expression was performed using Taqman 
reagents according to the manufacturer’s instructions 
(ER #Hs00174860_m1, TFF1 #Hs00907239_m1, PGR 
#Hs01556702_m1, GAPDH #Hs02758991_g1, GREB1 
#Hs00536409_m1, cyclinD1 #Hs00765553_m1, CDC25A 
#Hs00947994_m1). GAPDH for evaluating lungs was 
human #4352934e or mouse #4352932e. For genotyping 
of the D538G mutation, a custom CAST-PCR system was 
purchased from Life Technologies (SKU#/PPL 4476206, 
Quote# P1019473). 
Tissue culture
MCF7 (ATCC) were cultured in RPMI + 
L-glutamine (Gibco) with 10% FBS (Sigma) under 
normal conditions [56]. Stable cell lines were generated 
by lentiviral infection using standard techniques. ER 
vectors are in a pTRIPZ backbone and are doxycycline 
inducible. When evaluating ER expression, cells were 
plated with 1ug/ul doxycycline. 24hrs after plating, media 
was replaced with either fresh media containing 1ug/
ul doxycycline either with or without 20nM fulvestrant. 
Cells were incubated for 72hrs in fulvestrant before 
collecting and western blotting according to standard 
techniques. MCF-7 cells were genetically engineered 
to knock-in the ER Y537S mutation under neomycin 
selection. After two week of selection single cell clones 
were isolated and characterized. To confirm the knock-
in, a digital droplet PCR was performed [57] using 
ddPCR primers (CGGGTTGGCTCTAAAGTAGT 
and AATGCGATGAAGTAGAGCCC) and specific 
probes (BHQ_cc [C]ctc [tAt]gacc [t]g_HEX and 
BHQ_CC [A]CTC [TCT]GAC [C]TG_FAM). 
The location of the insertion was confirmed 
using junction PCR with the following primer 
pairs, 1 (TTAGATCATGCTGTAGGCCCTG) 
+ 2 (CTGGAACCCATGACCGGAAAG), 
3 (GCAGATCCAGGGGGCATTTA) + 
4 (GATGTGGAATGTGTGCGAGC), 2 
(CTGGAACCCATGACCGGAAAG) 5 
(GGATCAATTCTCTAGAGCTCGC). Tide analysis [58] 
was used to confirm the frame shift mutation of the 2nd 
ER allele. To measure ER-pS118, MCF7 cells were plated 
in charcoal/dextran stripped serum (Hyclone) for three 
days with daily washing with PBS to remove any residual 
estrogen. Where indicated, media with 10nM estrogen was 
added 24hr before harvesting. 
Antibodies
Vinculin (Sigma #V4505), ER antibodies: Santa 
Cruz cat# sc543 or Millipore #04-820), ER pS118 (Cell 
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Signalling #2511), ER for IHC (Ventana #790-4324 
[SP1]), p308-AKT (Cell Signaling #2965), p473-AKT 
(Cell Signaling #4060), AKT (Cell Signaling #4691), 
p240/244 S6 (Cell signaling #5364), p65-4EBP1 (Cell 
Signaling #9456), 4EBP1 (Cell Signaling #9452), 
cyclinD1 (Cell Signaling #2926), Rabbit IgG (Sigma, 
I5006). IHC: PR (1E2) Her2 (4B5) (Ventana Discovery 
XT). Biotinylated secondary antibodies (Vector Labs PK-
6101). 
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